Search research articles
Contact Us
Filters
Showing results (201-210 of 386) with videos related to
Page
of 39
Sort By:
Journal of Clinical Gastroenterology
|
November 2, 2013
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response
Stuart C Gordon, K Rajender Reddy, Ira M Jacobson, et al.
The American Journal of Gastroenterology
|
July 9, 2009
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients
Erik H C J Buster, Hajo J Flink, Halis Simsek, et al.
Hepatology Communications
|
February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B
Florian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Gastroenterology
|
December 10, 2013
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C
Maria Buti, Kosh Agarwal, Yves Horsmans, et al.
Lancet (London, England)
|
February 15, 2024
The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality
Tom H Karlsen, Harry Rutter, Patrizia Carrieri, et al.
Cancer
|
July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
W Ray Kim, Rohit Loomba, Thomas Berg, et al.
Gastroenterology
|
April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
Fabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 13, 2021
Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma
Daniel Q Huang, Joseph K Hoang, Jennifer Leong, et al.
Journal of Viral Hepatitis
|
March 15, 2021
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure
Damir Garcia-Cehic, Ariadna Rando, Francisco Rodriguez-Frias, et al.
Journal of Hepatology
|
April 7, 2009
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, et al.
Page
of 39
Search research articles
Search
Showing results (201-210 of 386) with videos related to
Sort By:
Page
of 39
Journal of Clinical Gastroenterology
|
November 2, 2013
Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response
Stuart C Gordon, K Rajender Reddy, Ira M Jacobson, et al.
The American Journal of Gastroenterology
|
July 9, 2009
Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients
Erik H C J Buster, Hajo J Flink, Halis Simsek, et al.
Hepatology Communications
|
February 26, 2025
Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B
Florian van Bömmel, Thierry Verbinnen, Kosh Agarwal, et al.
Gastroenterology
|
December 10, 2013
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C
Maria Buti, Kosh Agarwal, Yves Horsmans, et al.
Lancet (London, England)
|
February 15, 2024
The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality
Tom H Karlsen, Harry Rutter, Patrizia Carrieri, et al.
Cancer
|
July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
W Ray Kim, Rohit Loomba, Thomas Berg, et al.
Gastroenterology
|
April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
Fabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
March 13, 2021
Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma
Daniel Q Huang, Joseph K Hoang, Jennifer Leong, et al.
Journal of Viral Hepatitis
|
March 15, 2021
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure
Damir Garcia-Cehic, Ariadna Rando, Francisco Rodriguez-Frias, et al.
Journal of Hepatology
|
April 7, 2009
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, et al.
Page
of 39